PALO ALTO, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced that new Phase 3 ATTRibute-CM analyses and real-world evidence for acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, and the XX International Symposium on Amyloidosis (ISA) 2026 in Montevideo, Uruguay. At AHA 2026, BridgeBio had 2 moderated posters and 3 posters, and at ISA 2026, BridgeBio had 28 total abstracts accepted comprising 12 new poster presentations and 16 encore poster presentations. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.
At AHA 2026, a new ATTRibute-CM analysis presented by Mazen Hanna, M.D. of Cleveland Clinic, U.S. showed that acoramidis reduced heart failure (HF) events quickly and across the board.